Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The Lancet

• Publication date

  2016-08-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(16)30169-6PMID 27291994
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

  2015cited by this paper
• Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.

  2015cited by this paper
• Autologous hematopoietic stem cell transplantation in multiple sclerosis

  2015cited by this paper
• Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis

  2015cited by this paper
• Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis

  2014cited by this paper
• Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience

  2014cited by this paper
• Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

  2014cited by this paper
• Autologous hematopoietic stem cell transplantation following pulsed cyclophosphamide in a severely disabled patient with malignant multiple sclerosis

  2013cited by this paper
• Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation

  2013cited by this paper
• Characterising aggressive multiple sclerosis

  2013cited by this paper
• Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience

  2012cited by this paper
• Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

  2012cited by this paper
• Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation.

  2012cited by this paper
• Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis.

  2012cited by this paper
• Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research.

  2012cited by this paper
• *These authors contributed equally to this work.

  2012cited by this paper
• Diagnosis of multiple sclerosis.

  2011cited by this paper
• Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial

  2011cited by this paper
• Long-term results of stem cell transplantation for MS

  2011cited by this paper
• Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results

  2011cited by this paper
• Hematopoietic SCT for the treatment of multiple sclerosis

  2010cited by this paper
• Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases

  2010cited by this paper
• Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

  2010cited by this paper
• High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience

  2010cited by this paper
• Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis.

  2009cited by this paper
• A Three-Year Study of Brain Atrophy after Autologous Hematopoietic Stem Cell Transplantation in Rapidly Evolving Secondary Progressive Multiple Sclerosis

  2007cited by this paper
• Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients

  2007cited by this paper
• Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity

  2005cited by this paper
• Local magnetization transfer ratio signal inhomogeneity is related to subsequent change in MTR in lesions and normal-appearing white-matter of multiple sclerosis patients

  2005cited by this paper
• The multiple sclerosis severity score

  2003cited by this paper
• Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation

  2003cited by this paper
• Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores.

  2003cited by this paper
• Transfer of vitiligo after allogeneic bone marrow transplantation.

  2002cited by this paper
• Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis

  2002cited by this paper
• The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

  1991cited by this paper
• [Diagnosis of multiple sclerosis].

  1989cited by this paper
• Regimen-related toxicity in patients undergoing bone marrow transplantation.

  1988cited by this paper
• Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis

  1988cited by this paper
• Rating neurologic impairment in multiple sclerosis

  1983cited by this paper

• Bruton’s Tyrosine Kinase Inhibitors and Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis: A Review of Complementary Paradigms for a Divergent Disease

  2026cites this paper
• Cladribine tablets in the new multiple sclerosis era

  2025cites this paper
• Stem cells therapy in neurodegenerative and neuroimmune diseases: current status of treatments and future prospects.

  2025cites this paper
• BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party

  2025cites this paper
• Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT)

  2025cites this paper
• Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT

  2025influential citation
• Neuroimmune interactions: How past lessons can inform the present and future of MS care

  2025cites this paper
• Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation

  2025cites this paper
• Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study

  2025cites this paper
• Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions

  2025cites this paper
• Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis

  2025cites this paper
• Interaction Between Neutrophils and Elements of the Blood–Brain Barrier in the Context of Multiple Sclerosis and Ischemic Stroke

  2025cites this paper
• Autologous Stem Cell Transplantation for Multiple Sclerosis.

  2025cites this paper
• Outcomes of autologous stem cell transplantation in patients with multiple sclerosis: A United Arab Emirates experience.

  2025cites this paper
• De-escalating and discontinuing disease-modifying therapies in multiple sclerosis

  2024cites this paper
• Hydrogel-based approaches to target hypersensitivity mechanisms underlying autoimmune disease.

  2024cites this paper
• Optimizing Drug Selection in Children with Multiple Sclerosis: What Do We Know and What Remains Unanswered?

  2024cites this paper
• Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability?

  2024cites this paper
• Evoked potentials after autologous hematopoietic stem cell transplantation for multiple sclerosis.

  2024cites this paper
• Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis

  2024cites this paper
• Advances in hematopoietic stem cell transplantation for autoimmune diseases

  2024cites this paper
• Myeloid cell replacement is neuroprotective in chronic experimental autoimmune encephalomyelitis

  2024cites this paper
• The HSCT procedure (II): Conditioning, hematopoietic stem cell infusion, supportive care, and monitoring.

  2024cites this paper
• Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review

  2024cites this paper
• Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis.

  2024cites this paper
• Early and late complications of hematopoietic stem cell transplantation.

  2024cites this paper
• Smart Nanoscale Extracellular Vesicles in the Brain: Unveiling their Biology, Diagnostic Potential, and Therapeutic Applications.

  2024cites this paper
• Sclérose en plaques : traitements de fond

  2024cites this paper
• The HSCT procedure (I): Mobilization, collection, manipulation, and cryopreservation of a HSC graft.

  2024cites this paper
• Innovative Immunotherapies and Emerging Treatments in Type 1 Diabetes Management

  2024cites this paper
• Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis

  2024cites this paper
• Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial

  2024cites this paper
• Ongoing randomized clinical trials on HSCT in multiple sclerosis.

  2024cites this paper
• Optic Neuritis in the New Millennium

  2024cites this paper
• The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocols.

  2024cites this paper
• Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis.

  2024cites this paper
• Sclerosi multipla: trattamenti di base

  2024cites this paper
• Sequential immunotherapy: towards cures for autoimmunity

  2024cites this paper
• Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.

  2023cites this paper
• The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?

  2023cites this paper
• Autologous hematopoietic stem cell transplantation of patients with aggressive relapsing-remitting multiple sclerosis: Danish nation-wide experience.

  2023cites this paper
• Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life.

  2023cites this paper
• Congenic hematopoietic stem cell transplantation promotes survival of heart allografts in murine models of acute and chronic rejection.

  2023cites this paper
• Autologous Hematopoietic Stem Cell Transplantation to Treat Multiple Sclerosis

  2023cites this paper
• Autogreffe de cellules souches hématopoïétiques en neurologie inflammatoire

  2023cites this paper
• Is Autologous Hematopoietic Stem Cell Transplant Better Than High-Efficacy Disease-Modifying Therapies for Relapsing Multiple Sclerosis?

  2023cites this paper
• Potential of Nano-Engineered Stem Cells in the Treatment of Multiple Sclerosis: A Comprehensive Review

  2023cites this paper
• Antibody-Negative Stiff Person Syndrome Non-Responder After Hematopoietic Cell Transplant

  2023cites this paper
• Effect of Hematopoietic Stem Cell Transplantation and Post-Transplantation Cyclophosphamide on the Microglia Phenotype in Rats with Experimental Allergic Encephalomyelitis

  2023cites this paper
• Augmentation of a neuroprotective myeloid state by hematopoietic cell transplantation

  2023cites this paper
• Remission of severe myasthenia gravis after autologous stem cell transplantation

  2023cites this paper
• MRI graph parameters are longitudinal markers of neuronal integrity in multiple sclerosis.

  2023cites this paper
• Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis

  2023cites this paper
• Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation.

  2023cites this paper
• Immunological outcomes of autologous hematopoietic stem cell transplantation for multiple sclerosis: a systematic review

  2023cites this paper
• Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study

  2023cites this paper
• [Vaccination before and after autologous hematopoietic cell transplantation for autoimmune diseases: Guidances from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (MATHEC-SFGM-TC)].

  2023cites this paper
• The genealogy, methodology, similarities and differences of immune reconstitution therapies for multiple sclerosis and neuromyelitis optica.

  2022cites this paper
• High-dose immunosuppressive therapy with autologous hematopoietic stem cells transplantation for multiple sclerosis: Current view

  2022cites this paper
• High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis

  2022cites this paper
• Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis

  2022cites this paper
• Stammzelltransplantation bei Multipler Sklerose - wo stehen wir?

  2022cites this paper
• Impact of autologous HSCT on the quality of life and fatigue in patients with relapsing multiple sclerosis

  2022cites this paper
• Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline

  2022cites this paper
• Autologous Hematopoietic Stem-Cell Transplantation in Multiple Sclerosis: A Systematic Review and Meta-Analysis

  2022cites this paper
• Cell‐based experimental strategies for myelin repair in multiple sclerosis

  2022cites this paper
• A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis

  2022cites this paper
• Is stem cell transplantation safe and effective in multiple sclerosis?

  2022cites this paper
• Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis, the Ottawa Protocol

  2022cites this paper
• Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications

  2022cites this paper
• Potential application of hydrogel to the diagnosis and treatment of multiple sclerosis

  2022cites this paper
• The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis

  2022cites this paper
• Saudi Consensus Recommendations on the Management of Multiple Sclerosis: Disease-Modifying Therapies and Management of Relapses

  2022cites this paper
• Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Patients: Monocentric Case Series and Systematic Review of the Literature

  2022influential citation
• Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis

  2022cites this paper
• Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis

  2022cites this paper
• Case Report: Lessons Learned From Subsequent Autologous and Allogeneic Hematopoietic Stem Cell Transplantations in a Pediatric Patient With Relapsing Polychondritis

  2022cites this paper
• Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party

  2022cites this paper
• Pharmacologically Enhanced Regulatory Hematopoietic Stem Cells Revert Experimental Autoimmune Diabetes and Mitigate Other Autoimmune Disorders

  2022cites this paper
• High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: side effects and the tools of their reduction

  2022cites this paper
• Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?

  2022cites this paper
• Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations

  2021cites this paper
• New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis

  2021cites this paper
• Immune reconstitution therapy in NMOSD.

  2021cites this paper
• Autologous Stem Cell Transplant to Treat Recurrent Primary Sclerosing Cholangitis: Tolerance, but at What Price?

  2021cites this paper
• Impact of Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) on Treatment Cost of Multiple Sclerosis: Real-World Nationwide Study.

  2021cites this paper
• Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study

  2021cites this paper
• B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies

  2021cites this paper
• Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation

  2021cites this paper
• Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis

  2021cites this paper
• Neglected No More: Emerging Cellular Therapies in Traumatic Injury

  2021cites this paper
• Recent advances and remaining questions of autologous hematopoietic stem cell transplantation in multiple sclerosis.

  2021cites this paper
• Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

  2021cites this paper
• Outcomes of Bone Marrow Transplantation

  2021cites this paper
• Gene and cell therapy and nanomedicine for the treatment of multiple sclerosis: bibliometric analysis and systematic review of clinical outcomes

  2021cites this paper
• Long-term follow-up after lymphodepleting autologous hematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus.

  2021cites this paper
• Emerging concepts in the treatment of optic neuritis: mesenchymal stem cell-derived extracellular vesicles

  2021cites this paper
• Experiences of Relapsing Remitting Multiple Sclerosis and Disease Modifying Treatment: A phenomenological inquiry

  2021cites this paper
• Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis

  2021cites this paper
• Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’ multiple sclerosis

  2021cites this paper